Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences

Presentations will be Webcast Live and Archived on Vanda's Website

WASHINGTON, Aug. 23, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will present at two upcoming healthcare investor conferences during September 2012.

Vanda will present at the Stifel Nicolaus 2012 Healthcare Conference, being held in Boston, Massachusetts, on Wednesday September 5, 2012 at 4:25 p.m. Eastern Time.

On Friday September 7, 2012 Vanda will present at the BioCentury NewsMakers in the Biotech Industry Conference in New York City at 2:00 p.m. Eastern Time

Both conference presentations will be webcast live on Vanda's corporate website, where they will be archived for 30 days. To access the presentations, log on to http://www.vandapharma.com and click on the "Presentations" option in the Investor Relations section.  Please connect to the website several minutes prior to the start of the live presentation.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Company Contact:

Cristina Murphy
Senior Communications Manager
Vanda Pharmaceuticals Inc.
(202) 734-3414
[email protected]

SOURCE Vanda Pharmaceuticals Inc.

Suggested Articles

Passage Bio filed to raise $125 million in its IPO. Now, it has outraised that goal by $91 million with a $216 million Wall Street debut.

The ruling reflects the judge’s belief that the FDA’s interpretation of the law on clinical trial reporting “is unlawful and must be set aside.”

Trutino will apply a platform designed to yield safer, more effective cytokines to the discovery of three oncology drugs for Boehringer.